🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries

Recruitingn/aAges 18 Years - anyAllMédecins du Monde
NCT06395129 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Implementation and evaluation of a distribution program for low dead-space syringes/needles (LDSS/N) in Armenia, Georgia, and Tanzania, Egypt, Nigeria, Vietnam, India, Ukraine, and South Africa. This study aims to generate evidence on best practice LDSS/N distribution programs which will enhance acceptability and sustain high levels of LDSS/N uptake. People who inject drugs and access needle and syringe programs will be invited to attend up to three focus group discussion rounds (with 25 participants in each focus group round) to inform and provide feedback on a concurrent distribution program of LDSS/N. Throughout distribution, a cohort study will be run alongside distribution with 240 participants enrolled per country (with the exception of Nigeria, where 480 participants will be recruited) who will undergo HIV and HCV testing and answer surveys on their sociodemographic and behavior

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Aged ≥18 years (note that country-specific protocols may include participants aged ≥16 where appropriate and relevant); * Reporting a history of recent (past month) injection drug use; * Accessing the NSP to receive injecting equipment at either a facility, mobile service or through outreach and have an accompanying assigned program unique ID; * Able to understand and communicate in the local language(s); * If self-reporting HCV/HIV negative status, interested in and agreeing to undergo HCV and HIV testing; and * Willing and able to provide informed consent to take part in the study. Exclusion Criteria: * N/A
💊

What it tests

  • Low dead-space syringes/needles
  • Hepatitis C Antibody Rapid Diagnostic Test
  • HIV rapid Diagnostic Test
📍

Where

9 sites
Real World Real People
Yerevan, Armenia
Step to Future
Gori, Georgia
New Vector
Rustavi, Georgia
Hepa+
Tbilisi, Georgia
Mukikute
Dar es Salaam, Tanzania
Peer 2 Peer
Dar es Salaam, Tanzania
Yovaribe
Ilala, Tanzania
Mefada
Kinondoni, Tanzania

…and 1 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy